Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kinon, Bruce J
Chen, Lei
Ascher-Svanum, Haya
Stauffer, Virginia L
Kollack-Walker, Sara
Zhou, Wei
Kapur, Shitij
and
Kane, John M
2010.
Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia.
Neuropsychopharmacology,
Vol. 35,
Issue. 2,
p.
581.
Penfold, Robert B.
Kelleher, Kelly J.
Wang, Wei
Strange, Brandon
and
Pajer, Kathleen
2010.
Pediatric Uptake of a Newly Available Antipsychotic Medication.
Pediatrics,
Vol. 125,
Issue. 3,
p.
475.
Masdrakis, Vasilios G.
Florakis, Andreas
Tzanoulinos, Georgios
Markatou, Maria
and
Oulis, Panagiotis
2010.
Safety of the Electroconvulsive Therapy-Ziprasidone Combination.
The Journal of ECT,
Vol. 26,
Issue. 2,
p.
139.
Müller, Matthias J.
2011.
Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia.
Schizophrenia Research and Treatment,
Vol. 2011,
Issue. ,
p.
1.
Mattei, Chiara
Rapagnani, Maria Paola
and
Stahl, Stephen M.
2011.
Ziprasidone Hydrocloride: What Role in the Management of Schizophrenia?.
Journal of Central Nervous System Disease,
Vol. 3,
Issue. ,
p.
JCNSD.S4138.
Barnes, Thomas RE
2011.
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology.
Journal of Psychopharmacology,
Vol. 25,
Issue. 5,
p.
567.
Létourneau, Geneviève
Abdel-Baki, Amal
Dubreucq, Simon
Mahone, Michele
and
Granger, Béatrice
2011.
Hyperosmolar Hyperglycemic State Associated With Ziprasidone Treatment.
Journal of Clinical Psychopharmacology,
Vol. 31,
Issue. 5,
p.
671.
Carvajal, Alfonso
Martín Arias, Luis H.
and
Jimeno, Natalia
2011.
A worldwide yearly survey of new data in adverse drug reactions.
Vol. 33,
Issue. ,
p.
89.
Rossi, Alessandro
Cañas, Fernando
Fagiolini, Andrea
Larmo, Ilkka
Levy, Pedro
Montes, José Manuel
Papageorgiou, Georgios
Sturlason, Runa
Zink, Mathias
and
Correll, Christoph U.
2011.
Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone.
Postgraduate Medicine,
Vol. 123,
Issue. 1,
p.
135.
Hasan, Alkomiet
Falkai, Peter
Wobrock, Thomas
Lieberman, Jeffrey
Glenthoj, Birte
Gattaz, Wagner F.
Thibaut, Florence
and
Möller, Hans-Jürgen
2012.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
The World Journal of Biological Psychiatry,
Vol. 13,
Issue. 5,
p.
318.
Lindenmayer, J.
Tedeschi, Frank
Yusim, Anna
Khan, Anzalee
Kaushik, Saurabh
Smith, Robert
and
Parakadavil, Mohan
2012.
Ziprasidone's Effect on Metabolic Markers in Patients with Diabetes and Chronic Schizophrenia.
Clinical Schizophrenia & Related Psychoses,
Vol. 5,
Issue. 4,
p.
185.
Chen, Yuejin
Bobo, William V
Watts, Kara
Jayathilake, Karuna
Tang, Tinlai
and
Meltzer, Herbert Y
2012.
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Journal of Psychopharmacology,
Vol. 26,
Issue. 9,
p.
1201.
Lee, Hwang-Bin
Yoon, Bo-Hyun
Kwon, Young-Joon
Woo, Young Sup
Lee, Jung-Goo
Kim, Moon-Doo
and
Bahk, Won-Myong
2013.
The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study.
Clinical Drug Investigation,
Vol. 33,
Issue. 10,
p.
743.
Fraile, Miguel Gutiérrez
de la Gándara Martín, Jesús J.
and
García, Julio Bobes
2013.
Switching to Ziprasidone in the Clinical Practice Setting: An Open-Label Study.
The International Journal of Psychiatry in Medicine,
Vol. 45,
Issue. 2,
p.
125.
Honigberg, Michael C.
Bui, Melissa P.
and
Coconcea, Cristinel
2013.
A Case of Ziprasidone Associated with Acutely Worsened Diabetes Mellitus.
Psychosomatics,
Vol. 54,
Issue. 3,
p.
304.
Mandrioli, Roberto
Protti, Michele
and
Mercolini, Laura
2015.
Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.
Expert Opinion on Drug Metabolism & Toxicology,
Vol. 11,
Issue. 1,
p.
149.
2016.
Meyler's Side Effects of Drugs.
p.
577.
Murru, Andrea
Hidalgo, Diego
Bernardo, Miquel
Bobes, Julio
Saiz-Ruiz, Jerónimo
Álamo, Cecilio
and
Vieta, Eduard
2016.
Antipsychotic switching in schizoaffective disorder: A systematic review.
The World Journal of Biological Psychiatry,
Vol. 17,
Issue. 7,
p.
495.
Wang, Huai-Hai
Cai, Min
Wang, Hua-Ning
Chen, Yun-Chun
Zhang, Rui-Guo
Wang, Ying
McAlonan, Grainne M.
Bai, Yuan-Han
Wu, Wen-Jun
Guo, Li
Zhang, Ya-Hong
Tan, Qing-Rong
and
Zhang, Zhang-Jin
2017.
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Journal of Psychiatric Research,
Vol. 85,
Issue. ,
p.
59.
Panov, Georgi Panov
2022.
Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug.
Diagnostics,
Vol. 12,
Issue. 4,
p.
803.